Section 503A of the Federal Food, Drug, and Cosmetic Act is the pathway most clinics use when a patient needs a compounded medication: a strength, dosage form or combination that is not commercially available, prepared for that one patient on a valid prescription. The pharmacy doing that work is a 503A compounding pharmacy. It is licensed by its state board of pharmacy, must hold a non-resident license in every state it ships to, and operates under USP compounding standards rather than the manufacturing rules that apply to drug makers.
The practical problem for a growing practice is not finding a 503A pharmacy. It is managing five of them. Each pharmacy has its own portal, fax number, price list, licensing footprint and turnaround, and your staff end up re-keying the same patient into each one. ScriptLinkRx replaces that with one ordering platform in front of a vetted network of 503A compounding pharmacies.
What 503A ordering means for a clinic
Under 503A, every order starts with a prescription for an identified patient. That shapes the whole workflow:
- The prescriber decides. The clinician selects the medication, strength and directions for a specific patient. The pharmacy compounds to that prescription.
- The pharmacy must be licensed where the patient is. A pharmacy can only ship into states where it holds an active license.
- Copies of approved drugs are restricted. A 503A pharmacy may not regularly, or in inordinate amounts, compound a drug that is essentially a copy of a commercially available FDA-approved product, unless the prescriber documents a change that makes a significant difference for that patient. This matters most for GLP-1 products and for testosterone, where approved products exist.
- Compounded drugs are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality before they are dispensed. Clinics should present them to patients accordingly.
How an order flows on ScriptLinkRx
- Select the patient. Patient records live in the platform, with address validation so the pharmacy ships to a deliverable address the first time.
- Choose from one catalog. The catalog lists products from every partner pharmacy and only shows what can ship to that patient's state. Pharmacy pricing is visible before checkout.
- Prescribe and submit. The prescriber e-prescribes through the DoseSpot integration, including EPCS for controlled substances, and the order goes to the dispensing pharmacy with the patient details attached.
- Pay the way your practice works. Pay-by-clinic for practices that bill patients themselves, or a secure patient payment link for patient-pay models.
- Track to the door. Orders move through pharmacy review, compounding and shipment in one list, and patients receive tracking once the package ships. Refills are managed from the same record.
One network instead of five portals
Partner pharmacies on ScriptLinkRx list the states they are licensed in and the products they prepare. That gives a multi-state practice or a telehealth company a single place to order while still using independently licensed pharmacies. Today the network covers pharmacies licensed across all 50 states, and the clinic sees the same workflow whether an order ships from Texas or Florida.
Because each pharmacy sets its own pricing and turnaround, the platform surfaces those differences instead of hiding them. Staff can compare, and prescribers keep full control over what is written.
Compliance built into the workflow
The 2025 and 2026 FDA actions on compounded GLP-1 products made one thing clear: documentation lives or dies with the prescriber, and templated justifications do not hold up. ScriptLinkRx is designed around that reality:
- Prescriptions are written and signed by the prescriber, not generated from a pre-selected menu.
- Clinical notes and directions are entered per patient and travel with the order.
- Order history, receipts and prescription records are retained per patient and per business for audit and board inquiries.
- Pharmacy licensing is recorded on the platform so orders are not routed to a pharmacy that cannot lawfully ship to the patient.
For the current rules on specific categories, see the guides on compounded GLP-1 sourcing, peptides and testosterone.
503A or 503B?
503A is the patient-specific pathway. When a practice wants medication on hand for in-office administration without a prescription for a named patient, that is office-use ordering from a 503B outsourcing facility, which has its own rules and its own enrollment. The 503B office-use ordering guide covers the difference and how both run from one ScriptLinkRx account.
Sources
- FDA: Human Drug Compounding
- FDA: Compounding and the FD&C Act (sections 503A and 503B)
- FDA: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (guidance)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 2026)